Pharmaceutical Technology, Jan 2, 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Jan 2, 2014
Cover Story
The Future of Dosage Forms
By Patricia Van Arnum
How will the move to more specialized and personalized medicines impact drug delivery and dosage forms?
Drug Delivery
UK Biotech Gains Momentum
By Steve Bates
To gain insights into the current trends of the biotechnology sector in the United Kingdom, Pharmaceutical Technology Europe spoke with Steve Bates, chief executive officer of the BioIndustry Association (BIA), the trade association for biotech companies in the UK.
Featured Content
The Role of NMR and Mass Spectroscopy in Glycan Analysis
By Cynthia Challener, PhD
NMR analysis provides crucial structural information of synthesized glycans while LC-MS/MS is ideal for quantitation of free sugars in biological matrices.
Formulation
Challenges and Strategies for the Downstream Purification and Formulation of Fab Antibody Fragments
By Claire Scanlan , Jeffrey Shumway , Mark Wagner , Ruta Waghmare , Juan Castano
Antibody fragments pose unique challenges in terms of recovery, purification, and formulation.
Peer-Reviewed
Qualifying Personnel to Visually Inspect Cleaned Equipment
By Richard J. Forsyth
Different approaches for qualification of personnel for visual inspection of residues on equipment surfaces are reviewed.
API Synthesis and Manufacturing
A Look Ahead for Custom Manufacturing and Pharma
By Patricia Van Arnum
Emerging markets are an engine for growth in the custom-manufacturing and pharma markets.
Troubleshooting
Battling Off-Weight Tablets
By Matt Bundenthal
Training, calibration, and preventive maintenance help prevent over-and under-weight tablets. The author discusses causes of off-weight tablets and best practices for tableting.
Regulatory Watch
Early Communication with Regulators is Essential for SMEs
By Sean Milmo
With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.
Metrics Sought to Ensure Drug Quality
By Jill Wechsler
Regulators work with manufacturers to improve systems for measuring product performance and manufacturing reliability.
Outsourcing Outlook
R&D in Transition
By Jim Miller
The R&D model is in transition and creating new demands on contract services providers.
Statistical Solutions
Calibration of instruments: Is Your UV Spectrometer Accurate Enough
By Chris Burgess
This article takes a statistical look at the calibration requirements for a UV spectrometer.
Global Feature
Innovation and Market Growth in Brazil
By Hellen Berger
Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator.
Ask the Expert
Interactive Response Technologies for IP Temperature Excursions
By Kurt Lumsden
Kurt Lumden, Director, Client services at PAREXEL's Perceptive Informatics, discusses the management of investigational product temperature excursions.
Industry Leaders: Q&A
Q&A with Roger Hayes, MPI Research
By Melanie Sena
Roger Hayes of MPI Research discusses highly potent drug development.
From The Editor
Drugs At What Cost
By Rita Peters
Generics, market dynamics, and global demand are changing drug spending patterns.
Spotlight
ALpHA G Capsule Filter for Single-Use Systems
By Melanie Sena
ALpHA G Capsule Filter for Single-Use Systems
Gericke N200 Nibbler Provides Size Reduction
By Melanie Sena
Gericke N200 Nibbler Provides Size Reduction
Ribbon Blender Model 42N-270 Increases Performance
By Melanie Sena
Ribbon Blender Model 42N-270 Increases Performance
CS Inspection Machine Improves Efficiency
By Melanie Sena
CS Inspection Machine Improves Efficiency

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here